MedTrace Logo

CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Retrospective Cohort Study

NCT07240168 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-11-20

No results posted yet for this study

Summary

This study aims to evaluate whether adding CurQD, a nutraceutical composed of Curcumin and QingDai, improves treatment outcomes in patients with active ulcerative colitis (UC) who are already receiving Vedolizumab but still have ongoing disease activity. The study will use de-identified patient records collected through Evinature's global data platform. We will examine whether the addition of CurQD helps patients stay on Vedolizumab longer, improves symptoms and biomarkers, and increases satisfaction with treatment.

Conditions

  • Ulcerative Colitis (UC)

Interventions

DIETARY_SUPPLEMENT

CurQD (Curcumin + QingDai combination)

Patients received CurQD in addition to Vedolizumab

Sponsors & Collaborators

  • Sheba Medical Center

    collaborator OTHER_GOV

  • Takeda Pharmaceuticals U.S.A., Inc.

    collaborator UNKNOWN

  • Evinature Ltd.

    lead OTHER

Principal Investigators

  • Shomron Ben-Horin · Evinature Ltd.

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-07
Primary Completion
2026-08-20
Completion
2026-08-20

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240168 on ClinicalTrials.gov